Nephrology Perspective and Journal Articles

 
 

  • Heart Failure Guidelines Update: What the ESC Got Right   Heart failure specialist Dr Ileana Piña discusses what she likes about the 2023 ESC focused update to the heart failure guidelines.
  • Left-Digit Bias and Other Random Acts of Medicine   A new book reveals how chance can change the course of a person's health, life, and death.
  • Infographic: Doctors Act Out on Social Media, Peers See It Physicians discuss how they see other doctors posting on social media in ways they may regret, and which platforms have the biggest issues.
  • Change Makers: Elcin Barker Ergun on Healthcare Renaissance WebMD Chief Medical Officer John Whyte, MD, MPH, speaks with Elcin Barker Ergun, CEO of the Menarini Group, in Florence, Italy, about what they believe to be a new renaissance in healthcare.
  • S2 Episode 6: Neoadjuvant Therapy and Renal Cell Carcinoma   Drs Sumanta Pal and Jose A. Karam discuss neoadjuvant therapy in renal cell carcinoma, including TKIs, IO, and the need for more studies to explore the role of neoadjuvant therapy in RCC.
  • Pelvic Muscle Training and Incontinence After Prostatectomy Could pelvic floor muscle training help improve the symptoms of post-prostatectomy stress urinary incontinence? A new study evaluated the therapeutic effects.
  • The New Normal in Body Temperature   Are humans more cold-blooded than we have always believed? F. Perry Wilson reviews a study of "normal" oral temperatures in adults.
  • Wearable Health and Fitness Tech in Cardiovascular Medicine This review examines the various cardiovascular metrics provided by common consumer wearable devices. What are the potential pitfalls in interpreting and evaluating these metrics?
  • When Does a Bicarb Drip Make Sense? An older woman is admitted to the ICU with acidosis, AKI, and ketonuria. Will IV bicarb help or harm?
  • 'Decapitated' Boy Saved by Surgery Team   Dr F. Perry Wilson spoke with Dr Ohad Einav, the Israeli surgeon who repaired a boy's internal decapitation, the result of being struck by a car when riding his bike in the West Bank.
  • The Most Important Study From ESC If you treat patients, no trial at ESC is more important, according to John Mandrola, MD. The results of FRAIL-AF demonstrate the value of humility in science and the practice of evidence-based medicine.
  • Prophylactic and Early COVID-19 Treatment in Kidney Disease Pre-exposure prophylaxis and early post-exposure treatment may help reduce the severity of COVID-19 among patients with kidney disease.
  • Platelet to Albumin Ratio for Predicting pAKI in the ICU This study investigated whether the platelet to albumin ratio might be a useful biomarker in early identification of persistent acute kidney injury in patients admitted to the intensive care unit.
  • ESC 2023 AF Ablation in End-Stage HF: Too Good to Be True? Patients with AF and end-stage heart failure saw a dramatic early benefit from ablation. Some question the findings but others see a subset of patients for whom sinus rhythm makes a big difference.
  • Really? Cancer Screening Doesn't Save Lives?   You might have a hard time believing that all this cancer screening is for nothing. See what Perry thinks.
  • Infographic: Realities of Working as an Employed Physician Doctors who work for healthcare organizations and other employers tell of their happiness with their salaries, the importance of respect for their contributions, and where they would go for a new job.
  • Global Health Professionals Must Continue to Prevent Nuclear War A meaningful medical response to nuclear war is wishful thinking. Healthcare professionals, who know this better than anyone, must unite to prevent such a catastrophe.
  • Addressing Cardiovascular Risk in Diabetes In diabetes, a glycemic focus alone is not sufficient for addressing cardiovascular risk reduction, according to a new study.
  • Medication Safety in Chronic Kidney Disease Learn more about the medications that could cause drug-induced harm in patients with CKD.
  • ESC 2023 How Much AF Warrants Anticoagulation? Electrophysiologist John Mandrola reviews the NOAH-AFNET 6 trial presented at the European Society of Cardiology Congress 2023, which compared edoxaban vs placebo in patients with atrial high-rate episodes.